Once-Weekly Semaglutide in Adolescents with Obesity.

Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S

The New England journal of medicine2 Nov 2022Cited by 539 (Europe PMC)

PMID36322838PMCIDPMC9997064DOI10.1056/nejmoa2208601PepBankPUB-36322838

Source link PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adolescents with obesity, semaglutide 2.4 mg reduced BMI by 16.1% versus a 0.6% increase with placebo at week 68.
In plain wordsIn adolescents with obesity, semaglutide lowered body mass index much more than placebo over 68 weeks.
Peptide
Semaglutide
Outcome
DecreaseBMI percentage change at week 68
Study
n = 201
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
BMI change
−16.1%
semaglutide
BMI change
0.6%
placebo
Estimated difference
−16.7 percentage points
semaglutide vs placebo
Source sentences
Summary
The mean change in BMI from baseline to week 68 was -16.1% with semaglutide and 0.6% with placebo (estimated difference, -16.7 percentage points; 95% confidence interval [CI], -20.3 to -13.2; P<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.
Summary · context
Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention.
Summary · context
A total of 201 participants underwent randomization, and 180 (90%) completed treatment.
Report a problemFND-3632283801
02HumanRandomized controlled trialEfficacy outcome
In adolescents with obesity, more participants on semaglutide 2.4 mg than on placebo had weight loss of 5% or more at week 68 (73% versus 18%).
In plain wordsIn adolescents with obesity, more people on semaglutide than on placebo lost at least 5% of body weight over 68 weeks.
Peptide
Semaglutide
Outcome
IncreaseWeight loss of 5% or more at week 68
Study
n = 193
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Participants with weight loss >=5%
73%
semaglutide
Participants with weight loss >=5%
18%
placebo
Source sentences
Summary
At week 68, a total of 95 of 131 participants (73%) in the semaglutide group had weight loss of 5% or more, as compared with 11 of 62 participants (18%) in the placebo group (estimated odds ratio, 14.0; 95% CI, 6.3 to 31.0; P<0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.
Summary · context
Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention.
Summary · context
A total of 201 participants underwent randomization, and 180 (90%) completed treatment.
Report a problemFND-3632283802
03HumanRandomized controlled trialEfficacy outcome
In adolescents with obesity, reductions in body weight were greater with semaglutide 2.4 mg than with placebo.
In plain wordsIn adolescents with obesity, semaglutide reduced body weight more than placebo over 68 weeks.
Peptide
Semaglutide
Outcome
DecreaseBody weight reduction
Study
n = 201
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids [except high-density lipoprotein cholesterol], and alanine aminotransferase) were greater with semaglutide than with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.
Summary · context
Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention.
Summary · context
A total of 201 participants underwent randomization, and 180 (90%) completed treatment.
Report a problemFND-3632283803
04HumanRandomized controlled trialEfficacy outcome
In adolescents with obesity, waist circumference improved more with semaglutide 2.4 mg than with placebo.
In plain wordsIn adolescents with obesity, waist size improved more with semaglutide than with placebo over 68 weeks.
Peptide
Semaglutide
Outcome
DecreaseWaist circumference
Study
n = 201
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids [except high-density lipoprotein cholesterol], and alanine aminotransferase) were greater with semaglutide than with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.
Summary · context
Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention.
Summary · context
A total of 201 participants underwent randomization, and 180 (90%) completed treatment.
Report a problemFND-3632283804
05HumanRandomized controlled trialEfficacy outcome
In adolescents with obesity, glycated hemoglobin improved more with semaglutide 2.4 mg than with placebo.
In plain wordsIn adolescents with obesity, long-term blood sugar improved more with semaglutide than with placebo over 68 weeks.
Peptide
Semaglutide
Outcome
DecreaseHbA1c
Study
n = 201
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids [except high-density lipoprotein cholesterol], and alanine aminotransferase) were greater with semaglutide than with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.
Summary · context
Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention.
Summary · context
A total of 201 participants underwent randomization, and 180 (90%) completed treatment.
Report a problemFND-3632283805
06HumanRandomized controlled trialEfficacy outcome
In adolescents with obesity, lipid levels (except HDL cholesterol) improved more with semaglutide 2.4 mg than with placebo.
In plain wordsIn adolescents with obesity, blood fats other than HDL cholesterol improved more with semaglutide than with placebo over 68 weeks.
Peptide
Semaglutide
Outcome
Direction not reportedLipids except HDL cholesterol
Study
n = 201
Comparator
Placebo
Outcome group
Lipids · Cardiovascular
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids [except high-density lipoprotein cholesterol], and alanine aminotransferase) were greater with semaglutide than with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.
Summary · context
Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention.
Summary · context
A total of 201 participants underwent randomization, and 180 (90%) completed treatment.
Report a problemFND-3632283806
07HumanRandomized controlled trialEfficacy outcome
In adolescents with obesity, alanine aminotransferase improved more with semaglutide 2.4 mg than with placebo.
In plain wordsIn adolescents with obesity, a liver blood marker improved more with semaglutide than with placebo over 68 weeks.
Peptide
Semaglutide
Outcome
Direction not reportedAlanine aminotransferase
Study
n = 201
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Source sentences
Summary
Reductions in body weight and improvement with respect to cardiometabolic risk factors (waist circumference and levels of glycated hemoglobin, lipids [except high-density lipoprotein cholesterol], and alanine aminotransferase) were greater with semaglutide than with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.
Summary · context
Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention.
Summary · context
A total of 201 participants underwent randomization, and 180 (90%) completed treatment.
Report a problemFND-3632283807
08HumanRandomized controlled trialSafety outcome
In adolescents with obesity, gastrointestinal adverse events were more frequent with semaglutide 2.4 mg than with placebo (62% versus 42%).
In plain wordsIn adolescents with obesity, stomach and gut side effects were more common with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n = 200
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Gastrointestinal adverse events
62%
semaglutide
Gastrointestinal adverse events
42%
placebo
Source sentences
Summary
The incidence of gastrointestinal adverse events was greater with semaglutide than with placebo (62% vs. 42%).
3 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.
Summary · context
Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention.
Summary · context
A total of 201 participants underwent randomization, and 180 (90%) completed treatment.
Report a problemFND-3632283808
09HumanRandomized controlled trialSafety outcome
In adolescents with obesity, five participants (4%) on semaglutide 2.4 mg had cholelithiasis versus none on placebo.
In plain wordsIn adolescents with obesity, gallstones occurred in five people on semaglutide and in none on placebo.
Peptide
Semaglutide
Outcome
IncreaseCholelithiasis
Study
n = 200
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Participants with cholelithiasis
5 participants
semaglutide
Source sentences
Summary
Five participants (4%) in the semaglutide group and no participants in the placebo group had cholelithiasis.
3 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.
Summary · context
Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention.
Summary · context
A total of 201 participants underwent randomization, and 180 (90%) completed treatment.
Report a problemFND-3632283809
10HumanRandomized controlled trialSafety outcome
In adolescents with obesity, serious adverse events were reported in 11% of participants on semaglutide 2.4 mg and 9% on placebo.
In plain wordsIn adolescents with obesity, serious side effects were reported in 11% of people on semaglutide and 9% on placebo.
Peptide
Semaglutide
Outcome
Not applicableSerious adverse events
Study
n = 200
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Participants with serious adverse events
11%
semaglutide
Participants with serious adverse events
9%
placebo
Source sentences
Summary
Serious adverse events were reported in 15 of 133 participants (11%) in the semaglutide group and in 6 of 67 participants (9%) in the placebo group.
3 context sentences(design, population, supporting numbers)
Summary · context
In this double-blind, parallel-group, randomized, placebo-controlled trial, we enrolled adolescents (12 to <18 years of age) with obesity (a body-mass index [BMI] in the 95th percentile or higher) or with overweight (a BMI in the 85th percentile or higher) and at least one weight-related coexisting condition.
Summary · context
Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide (at a dose of 2.4 mg) or placebo for 68 weeks, plus lifestyle intervention.
Summary · context
A total of 201 participants underwent randomization, and 180 (90%) completed treatment.
Report a problemFND-3632283810

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 4NCT07590219

Use of Liraglutide in Children Aged 6 to 12 Years With Severe Obesity

University of Sao Paulo General Hospitaln = 3030 Mar 2024 to est. Apr 2028

Severe Obesity · Cardiovascular Function · Liraglutide · Childhood Obesity · Echocardiography · Speckle Tracking

Trial page ClinicalTrials.govUpdated 15 May 2026

CompletedPhase 3Results postedNCT04102189

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Novo Nordisk A/Sn = 2017 Oct 2019 to 28 Mar 2022

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 11 Dec 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.